company’s lead program, TSND-201 (methylone), is being developed as a next-generation neuroplastogen designed to deliver fast and durable therapeutic effects. Its research emphasizes innovative psychoactive compounds that can improve outcomes while minimizing common limitations of traditional psychiatric medications. Backed by venture funding and an experienced leadership team with multiple FDA approvals, Transcend Therapeutics continues to advance clinical trials and expand its pipeline of mental health treatments.